Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Robinhood posted 27% revenue growth in its latest quarter (the weakest in two years) and analysts expect Q1 revenue growth to decelerate to ~26%; the stock is down ~38% YTD. GeneDx grew revenue 40% to $427.5M last year (after +51% prior year) and remains a multi-bagger since its 1-for-33 reverse split, but shares have plunged >60% from a December peak even as analysts model ≥20% revenue growth annually over the next four years. Tesla is down ~23% YTD after its first year of declining revenue in 2025; analysts expect growth to resume, and Ark Invest (Cathie Wood) added to positions — Tesla represents ~9% of Ark's combined holdings.

Analysis

Robinhood’s current derating looks less like a pure user-exit story and more like a funding-and-credit shock playing out through a retail margin channel: smaller customer balances + forced deleveraging compresses both transaction flow and interest income simultaneously, creating a convex downside in revenue over the next 1–3 quarters if markets stall further. The company’s pivot into futures and predictive markets increases user stickiness but substitutes correlation risk (macro/crypto volatility) for idiosyncratic retention; that means upside from a market rebound is quick but downside is deeper and faster, shifting optimal hedge tenors toward near-term (30–90 day) protection rather than long-dated puts.

GeneDx’s pullback appears to price in an outsized reimbursement/shock scenario rather than gradual secular adoption: sequencing volumes and pricing power can materially beat consensus over 12–24 months if payer coverage expands and reference-lab consolidation preserves mix; conversely, a single large payor pushback would knock 2–4 quarters off growth. A less-obvious positive is the rising compute/content demand from clinical genomics — Nvidia/Intel exposure via compute partners (and cloud sequencing economics) is a multipler for GeneDx’s gross margins over time, creating a pathway for operating leverage without large capex on GeneDx’s balance sheet.

Tesla’s optionality is increasingly bifurcated: core vehicle margins face near-term headwinds from model rationalization, while energy, services and software (FSD/taxi prospects) produce multi-year asymmetric upside if regulatory and fleet economics align; those are binary catalysts that can re-rate the stock by multiples but with long, uncertain timelines. Ark’s consistent buying functions as a structural bid on drawdowns and reduces immediate tail liquidity risk, but it’s not a substitute for the fundamental catalysts (software monetization + robotaxi commercialization) that need to materialize over 12–36 months to justify a higher valuation.

Key Decisions for Investors

• Short HOOD via a 3-month put spread: buy 25–30 delta puts and sell 10–15 delta puts, position size 1–2% portfolio. Rationale: pays off if market/crypto stay weak into next earnings cycle; target return 2.5–3x premium if shares decline ~30%; max loss = premium paid (defined).
• Hedge-market pair: short HOOD equity (or add to above put spread) and pair with a tactical long NVDA on 1–3 month dips (buy-to-open 45–60 delta calls or stock). Rationale: rotation from retail/fintch into AI-driven compute could outperformance; expect 2:1 asymmetric payoff if tech rally resumes within 3 months.
• Long WGSWW (small, conviction-weighted) + buy 12–18 month OTM calls as leverage, size 0.5–1% portfolio. Rationale: secular genomic adoption and operating leverage create >3x upside over 12–24 months if reimbursement stabilizes; downside risk is concentrated payor pressure — cap losses to equity stake size or use calls to limit downside.
• Directional TSLA exposure via 9–12 month call spread (buy 50-delta call, sell 70–75-delta call) sized to 1–3% portfolio. Rationale: captures software/energy upside while limiting Vega/decay; target 2–3x return if software monetization or energy growth re-accelerates within 12 months, max loss = net premium.